TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InnoCare Pharma Ltd. ( (HK:9969) ) has issued an update.
InnoCare Pharma Ltd. has announced that its board of directors will meet on August 19, 2025, to consider and approve the interim financial results for the first half of the year. This meeting could have significant implications for the company’s financial transparency and investor relations, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$11.76 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies. The company operates within the healthcare industry, primarily targeting the treatment of cancer and autoimmune diseases.
Average Trading Volume: 18,293,230
Technical Sentiment Signal: Buy
Current Market Cap: HK$26.3B
For an in-depth examination of 9969 stock, go to TipRanks’ Overview page.